Comparative Pharmacology
Head-to-head clinical analysis: METATENSIN 4 versus SALUTENSIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METATENSIN 4 versus SALUTENSIN.
METATENSIN #4 vs SALUTENSIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing cGMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
Salutensin is a combination of two antihypertensive agents: hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption; and reserpine, a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine) from presynaptic nerve terminals by irreversibly blocking vesicular monoamine transporter (VMAT), leading to decreased peripheral vasoconstriction and heart rate.
2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.
Oral, 1 tablet (50 mg spironolactone + 5 mg bendroflumethiazide) once daily. Maximum 2 tablets per day.
None Documented
None Documented
12-18 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 18-24 hours (mean 20 h); clinically, requires 5-7 days to reach steady state; prolonged in renal impairment (CrCl <30 mL/min: up to 40 h) and in elderly.
Renal (70% unchanged, 20% as metabolites); biliary/fecal (10%)
Primarily renal (65-75% as unchanged drug); biliary/fecal (20-30%) with enterohepatic recirculation; minor metabolism via CYP3A4 to inactive metabolites.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination